Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis

Current Medical Research and Opinion

Volumn 26, Issue 9, 2010, Pages 2047-2055

  Baena Cagnani, Carlos E ^a,b   Patel, Piyush ^c  

^a Chutro Clinic   (Argentina)

^b UNIVERSITY OF GENOA   (Italy)

^c Allied Research International   (Canada)

Author keywords

Adverse events; Children; Intranasal corticosteroids; Persistent allergic rhinitis

Indexed keywords

MOMETASONE FUROATE; PLACEBO;

AEROSOL; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE DISEASE; OPEN STUDY; PATIENT COMPLIANCE; PERENNIAL RHINITIS; PHASE 3 CLINICAL TRIAL; PHYSICIAN; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SNEEZING; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ANTI-ALLERGIC AGENTS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NASAL SPRAYS; PLACEBOS; PREGNADIENEDIOLS; RHINITIS, ALLERGIC, PERENNIAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955649670     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.487661     Document Type: Article

References (57)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
2. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007;28:3-9
3. Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol 2002;88:2-7
4. Allergies in AmericaTM: a landmark survey of nasal allergy sufferers. Executive summary: pediatrics. Available at http://www.mmcpub.com/scsaia/ PedSummary.pdf [Last accessed 14 July 2009]
5. Lack G. Pediatric allergic rhinitis and comorbid disorders. J Allergy Clin Immunol 2001;108:S9-15
6. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001;108:S45-53
7. Management of allergic and nonallergic rhinitis: summary of evidence report/technology assessment No. Agency for Healthcare Research and Quality, May 2002. Available at: http://www.ahrq.gov/clinic/epcsums/rhinsum.htm [Last accessed 14 July 2009]
8. Wright AL, Holberg CJ, Martinez FD, et al. Epidemiology of physiciandiagnosed allergic rhinitis in childhood. Pediatrics 1994;94:895-901
9. Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007;120: 381-387
10. Fireman P. Therapeutic approaches to allergic rhinitis: treating the child. J Allergy Clin Immunol 2000;105:S616-21
11. Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000;105:S622-7
12. Dykewicz MC, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol 1998;81:463-468
13. Mion O, de Mello Jr. JF, Lessa MM, et al. The role of rhinitis in chronic otitis media. Otolaryngol Head Neck Surg 2003;128:27-31
14. Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma (ARIA). In collaboration with the World Health Organization. Executive summary of the workshop report 7-10 December 1999, Geneva, Switzerland. Allergy 2002;57:841-855
15. Gawchik SM, Saccar CL. A risk-benefit assessment of intranasal triamcinolone acetonide in allergic rhinitis. Drug Saf 2000;23:309-322
16. Bousquet J, van Cauwenberge P, Ät Khaled N, et al. GA2LEN. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy 2006;61:1086-1096
17. Scadding GK. Corticosteroids in the treatment of pediatric allergic rhinitis. J Allergy Clin Immunol 2001;108:S59-64
18. Meltzer EO. The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy 1997; 52:33-40
19. Penagos M, Compalati E, Tarantini F, et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis: meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy 2008;63: 1280-1291
20. Má spero JF, Rosenblut A, Finn Jr A, et al. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg 2008;138:30-37
21. Baena-Cagnani CE. Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf 2004;27:883-898
22. Fokkens WJ, Cserhati E, dos Santos JM, et al. Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. Ann Allergy Asthma Immunol 2002;89: 279-284
23. Milgrom H, Biondi R, Georgitis JW, et al. Comparison of ipratropium bromide 0.03% with beclomethasone dipropionate in the treatment of perennial rhinitis in children. Ann Allergy Asthma Immunol 1999;83: 105-111
24. Ngamphaiboon J, Thepcharti A, Chatchatee P, et al. Fluticasone propionate aqueous nasal spray treatment for perennial allergic rhinitis in children. Ann Allergy Asthma Immunol 1997;78:479-484
25. Welch MJ, Bronsky EA, Grossman J, et al. Clinical evaluation of triamcinolone acetonide nasal aerosol in children with perennial allergic rhinitis. Ann Allergy 1991;67:493-498
26. Baena-Cagnani CE, Passalacqua G, Gómez M, et al. New perspectives in the treatment of allergic rhinitis and asthma in children. Curr Opin Allergy Clin Immunol 2007;7:201-206
27. Benninger MS, Ahmad N, Marple BF. The safety of intranasal steroids. Otolaryngol Head Neck Surg 2003;129:739-750
28. Boner AL. Effects of intranasal corticosteroids on the hypothalamic-pituitaryadrenal axis in children. J Allergy Clin Immunol 2001;108:S32-9
29. Wilson AM, Sims EJ, McFarlane LC, et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998;102:598-604
30. Kim KT, Rabinovitch N, Uryniak T, et al. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol 2004;93:61-67
31. Galant SP, Wilkinson R. Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options? BioDrugs 2001;15:453-463
32. Nasonex [package insert]. Kenilworth, NJ: Schering Corporation, 2005
33. Veramyst [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2007
34. Nasacort AQ [package insert]. Bridgewater, NJ: sanofi-aventis US LLC, 2006
35. Flonase [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2004
36. Beconase [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2005
37. Rhinocort Aqua [package insert]. Wilmington, DE; Astra Zeneca LP, 2005
38. Nasarel [package insert]. Miami, FL: Ivax Laboratories Inc., 2006
39. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 1999;104:948-952
40. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105:E22[1-7]
41. Berkowitz RB, Bernstein DI, LaForce C, et al. Onset of action of mometasone furoate nasal spray (NASONEX-) in seasonal allergic rhinitis. Allergy 1999; 54:64-69
42. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997; 19:1330-1339
43. Bronsky EA, Aaronson DW, Berkowitz RB, et al. Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:51-56
44. Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (NasonexTM) in seasonal allergic rhinitis: an active-and placebo-controlled study. Allergy 1996;51:569-576
45. Meltzer EO, Berger WE, Berkowitz RB, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:107-114
46. Canonica GW, Baena-Cagnani CE, Blaiss MS, et al. for the GAPP Survey Working Group. Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) Survey: global adult findings. Allergy 2007;62:668-674
47. Gradman J, Caldwell MF, Wolthers OD. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis. Clin Ther 2007;29:1738-1747
48. Galant SP, Melamed IR, Nayak AS, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2-and 3-year-old patients. Pediatrics 2003;112:96-100
49. Fluticasone Propionate Collaborative Pediatric Working Group. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. J Pediatr 1994;125:628-634
50. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics 1993;92:594-599
51. Mö ller C, Ahlström H, Henricson KA, et al. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 2003;33:816-822
52. Nayak AS, Ellis MH, Gross GN, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocorticol function in children with allergic rhinitis. J Allergy Clin Immunol 1998;101:157-162
53. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000;105:e23
54. Mansfield LE, Mendoza CP. Medium and long-term growth in children receiving intranasal beclomethasone dipropionate: a clinical experience. South Med J 2000;95:334-340
55. Murphy K, Uryniak T, Simpson B, et al. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol 2006;96:723-730
56. Ober S, Gentile D, Kairis E, et al. Growth velocity and HPA axis function during 1-year treatment with triamcinolone acetonide aqueous (TAA) nasal spray in children with allergic rhinitis (AR). J Allergy Clin Immunol 2005;115:S267 [Abstract 1064]
57. Allen DB, Meltzer EO, Lemanske Jr RF, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002;23:407-413